Both Companies

Also showing items for Both Research

 
Stock Quotes for Both Companies top ^
  • Industry: Conglomerates
  • Sector: Industrials
  • Stock Type: Cyclical
Sign-up for both investment picks
  • Industry: Conglomerates
  • Sector: Industrials
  • Stock Type: Cyclical
Sign-up for both investment picks

 
News Articles for Both Companies top ^
MicroWave Technology Inc. (MwT), a division of IXYS Corporation (NASDAQ: IXYS), announced that it offers a family of MMIC products that are fully compatible with both epoxy and AuSn eutectic alloy die attachment methods.
Sign-up for MicroWave Technology Inc. Releases GaAs Based Advanced MMIC Products Compatible with both Epoxy and AuSn Eutectic Die Attachment Processes investment picks
First Trust Intermediate Duration Preferred & Income Fund (the “Fund”) (NYSE: FPF) has declared the Fund’s regularly scheduled monthly common share distribution and special distribution, both in the amount of $0.1625 per share payable on January 15, 2015, to shareholders of record as of December 31, 2014.
Sign-up for First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution and Special Distribution, both in the amount of $0.1625 Per Share investment picks
2014/11/6
By Philip van Doorn, MarketWatch The most important theme for Tesla Motor Inc.'s shareholders isn't revenue or profits.
Sign-up for UPDATE: Tesla's stock is somehow both speculative and a good value investment picks
2014/11/5
By Philip van Doorn, MarketWatch The most important theme for Tesla Motor Inc.'s shareholders isn't revenue or profits.
Sign-up for UPDATE: Tesla's stock is somehow both speculative and a good value investment picks
2014/11/3
By Catey Hill, MarketWatch In case you were wondering, Republicans and Democrats CAN find more things to disagree on -- even things as seemingly mundane as bookstores and snack foods.
Sign-up for UPDATE: What GOP and Dems agree on: Both dislike Motel 6 and Chuck E. Cheese investment picks
2014/10/30
The Company is filing this amendment to the Press Release filed on October 30, 2014 solely to correct the information regarding the percentage of shares voted in favor of the proposals.
Sign-up for Amendment: Salisbury Bancorp, Inc. and Riverside Bank Announce Approval of Their Proposed Merger by the Shareholders of Both Companies investment picks
2014/10/30
By Catey Hill, MarketWatch In case you were wondering, Republicans and Democrats CAN find more things to disagree on -- even things as seemingly mundane as bookstores and snack foods.
Sign-up for UPDATE: What GOP and Dems agree on: Both dislike Motel 6 and Chuck E. Cheese investment picks
Clovis Oncology (NASDAQ:CLVS) today announced initial Phase 2 results from the ARIEL2 (Assessment of Rucaparib In Ovarian Cancer Trial) study.
Sign-up for Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients investment picks
2014/11/19
http://media.marketwire.com/attachments/201411/292077_Logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1160213&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Shopper Study Shows Physical Stores Drive Sales Both On and Offline investment picks
Thanksgiving Posts 32% Gain to $1.0 Billion While Black Friday Jumps 26% to $1.5 Billion Pushing Season-to-Date Growth Rate to 15% RESTON, Va.
Sign-up for Thanksgiving and Black Friday See Online Buying Bonanza as Both Days Surpass $1 Billion in Desktop Spending investment picks
AstraZeneca (NYSE:AZN) today announced that the PEGASUS-TIMI 54 study, a large scale outcomes trial involving over 21,000 patients, successfully met its primary efficacy endpoint.
Sign-up for PEGASUS-TIMI 54 Study of BRILINTA® Meets Primary Endpoint in Both 60mg and 90mg Doses investment picks
Celgene International Sàrl (NASDAQ: CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has granted marketing authorisation for OTEZLA ® (apremilast), the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications: 1 “The approval of OTEZLA ® is an important new option for the treatment of patients who are not experiencing adequate relief for their conditions.
Sign-up for Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Both Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Boston Private Financial  |  Next: Both Research